IN VITRO AND IN VIVO LABORATORY STUDIES ON THREE HYDROXYIMINOPHENYLACETYL CEPHALOSPORINS WITH PARTICULAR REFERENCE TO SK&F 80303, AN UNUSUALLY LONG-ACTING CEPHALOSPORIN

Three cephalosporins with 7-(2-hydroxyiminophenylacetamido) side chains (SK&F 79433, 80000 and 80303), differing in their 3-substituents, exhibited similar broad-spectrum antibacterial activity in vitro against strains of Staphylococcus aureus, Streptococcus faecalis and various Gram-negative ba...

Full description

Saved in:
Bibliographic Details
Published inJournal of antibiotics Vol. 32; no. 11; pp. 1161 - 1167
Main Authors URI, JOSEPH V., ACTOR, PAUL, ZAJAC, IHOR, PITKIN, DONALD H., PHILLIPS, LILLIAN, GUARINI, JOSEPH R., BARTUS, HENRY F., POLANSKY, THEODORE J., DUNN, GEORGE L., HOOVER, JOHN R. E., WEISBACH, JERRY A.
Format Journal Article
LanguageEnglish
Published Japan JAPAN ANTIBIOTICS RESEARCH ASSOCIATION 1979
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Three cephalosporins with 7-(2-hydroxyiminophenylacetamido) side chains (SK&F 79433, 80000 and 80303), differing in their 3-substituents, exhibited similar broad-spectrum antibacterial activity in vitro against strains of Staphylococcus aureus, Streptococcus faecalis and various Gram-negative bacilli. All three were active in vivo (s.c., mouse) against S. aureus, Esclrerichia coli or Klebsiella pnemnoniae, but they differed significantly in serum pharmacokinetic profiles. SK&F 80303 produced high and extremely prolonged serum levels and protected mice when administered up to 24 hours prior to challenge with β-lactamase-producing S. aureus or K. pneumoniae NS. It was resistant to hydrolysis by β-lactamases from S. aureus, and variably so to β-lactamases from E. coli strains. SK&F 80303 was bacteriolytic to logarithmically growing S. aureus, E. coli, Proteus mirabilis, K. pneumoniae and Enterobacter cloacae (partially).SK&F 80303 illustrates further the effect of the 3-sulfoalkyltetrazole substituent on the pharmacokinetic properties of cephalosporins. Its combined biological properties make it a possible candidate for therapeutic and long-term prophylactic use.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-8820
1881-1469
DOI:10.7164/antibiotics.32.1161